100 Beaver Street
Steven M. Rauscher, president and CEO
Genome Therapeutics Corp. commercializes genomics-based drug discoveries for pharmaceutical, vaccine and diagnostic products. Its gene discovery program, with new initiatives in functional genomics and pharmacogenomics, identifies and characterizes human genes associated with major diseases and bacterial genes responsible for infectious diseases.
The company’s PathoGenome Database, a comprehensive commercial source of microbial genomic information, is available on the Internet through LabOnWeb.com. The database enables researchers to search for new genes among multiple pathogens and cross-reference genomic information for the development of new anti-infective products.
Genome Therapeutics also offers sequencing services through its GenomeVision services, which include library construction, sequencing and confirmation sequencing services, project finishing, assembly and annotation, SNP discovery and screening and quality control testing and validation.
Genome Therapeutics is a research center for the Human Genome Project and the Rat Genome Project.
Genomic Therapeutics’ partners in infectious diseases and in human genomics include Astra AB, bioMérieux Inc., Schering-Plough Corp. and Wyeth-Ayerst Laboratories. The company also has collaborations in osteoporosis, anti-infectives development, antibiotic resistance and/or SNP technology with ArQule Inc., Icagen, Creighton University, Northeastern University and Ohio State University.
Subscribers to the PathoGenome Database include Aventis SA, Anadys Pharmaceuticals Inc., Bayer AG, bioMérieux Inc., Bristol-Myers Squibb Co., Compugen Inc. and Schering-Plough Corp.
Genomics services customers include AstraZeneca plc, Aventis SA, Biogen Inc., Cubist Pharmaceuticals Inc., the Human Genome Project, Memorial Sloan-Kettering Cancer Center, the Mouse Genome Sequencing Network, Phylos Inc., Schering-Plough Corp. and Cancer Research Center Queen’s University, Ireland.